One year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump administration ...
The big takeaway from the recent Alzheimer’s Association International Conference in London is an economic message: Dementia ...
The world risks a resurgence of the HIV epidemic after international financing to combat the disease suffered a “profound ...
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another ...
Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooters,” write CHOP’s ...
Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an ...
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...
Even as some medical schools heed health secretary Robert F. Kennedy Jr.’s call for more nutrition education, several told ...
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Sarepta Therapeutics, the bruised ...
Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare Advantage, opaque prescription drug benefits, and how much executives actually make. He ...
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sarepta Therapeutics’ CEO Doug Ingram said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results